This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Pfeffer, L. M. Articles by Donner, D. B. Search for Related Content PubMed PubMed Citation Articles by Pfeffer, L. M. Articles by Donner, D. B.

The Down-Regulation of -Interferon Receptors in Human Lymphoblastoid Cells: Relation to Cellular Responsiveness to the Antiproliferative Action of -Interferon¹

Laboratory of Cell Physiology and Virology, The Rockefeller University [L. M. P.] and Program in Cell Biology and Genetics, Memorial Sloan-Kettering Cancer Center [D. B. D.], New York, New York 10021

Human lymphoblastoid cell lines (Daudi, Daudi subclones, Raji and MOLT-4) were compared for sensitivity to the antiproliferative action of -interferon (IFN-) and down-regulation of IFN- receptors. IFN-sensitive and IFN-resistant cell lines have similar numbers (2–4000/cell) of high affinity (20–75 pM) IFN- receptors. Treatment of IFN-sensitive cells with low concentrations (3–10 pM) of IFN- results in low receptor occupancy and nearly complete (> 95%) down-regulation of cell surface IFN- receptors within 5 h. Treatment of resistant cells with higher IFN concentrations (30 pM) only results in partial (60%) receptor down-regulation that is directly related to receptor occupancy. Receptor-receptor interactions, induced by IFN- binding, may account for the enhanced down-regulation of IFN- receptors in IFN-sensitive cells. Such interactions apparently do not occur in IFN-resistant lymphoblastoid cell lines.

¹ This work was supported by grants from the NIH (GM 36716, CA 44747, and DK 30788) and by a grant from the New York State Health Research Council. L. M. P. is a Leukemia Society of America Scholar.

² To whom requests for reprints should be addressed, at The Rockefeller University, 1230 York Avenue, New York, NY 10021-6399.

Received 7/20/89. Revised 1/10/90.

This article has been cited by other articles:

				C. H. Yang, L. Wei, S. R. Pfeffer, Z. Du, A. Murti, W. J. Valentine, Y. Zheng, and L. M. Pfeffer Identification of CXCL11 as a STAT3-Dependent Gene Induced by IFN J. Immunol., January 15, 2007; 178(2): 986 - 992. [Abstract] [Full Text] [PDF]

				S. A. Brod Ingested Type I Interferon: State of the Art as Treatment for Autoimmunity Experimental Biology and Medicine, December 1, 2002; 227(11): 981 - 988. [Abstract] [Full Text]

				S. A. Brod, J. W. Lindsey, F. S. Vriesendorp, C. Ahn, E. Henninger, P. A. Narayana, and J. S. Wolinsky Ingested IFN-{alpha}: Results of a pilot study in relapsing-remitting MS Neurology, September 11, 2001; 57(5): 845 - 852. [Abstract] [Full Text] [PDF]

				C.-H. Yang, A. Murti, and L. M. Pfeffer STAT3 complements defects in an interferon-resistant cell line: Evidence for an essential role for STAT3 in interferon signaling and biological activities PNAS, May 12, 1998; 95(10): 5568 - 5572. [Abstract] [Full Text] [PDF]

				L. H. Wong, K. G. Krauer, I. Hatzinisiriou, M. J. Estcourt, P. Hersey, N. D. Tam, S. Edmondson, R. J. Devenish, and S. J. Ralph Interferon-resistant Human Melanoma Cells Are Deficient in ISGF3 Components, STAT1, STAT2, and p48-ISGF3gamma J. Biol. Chem., November 7, 1997; 272(45): 28779 - 28785. [Abstract] [Full Text] [PDF]

				K. A. Holland, C. M. Owczarek, S. Y. Hwang, M. J. Tymms, S. N. Constantinescu, L. M. Pfeffer, I. Kola, and P. J. Hertzog A Type I Interferon Signaling Factor, ISF21, Encoded on Chromosome 21 Is Distinct from Receptor Components and Their Down-regulation and Is Necessary for Transcriptional Activation of Interferon-regulated Genes J. Biol. Chem., August 22, 1997; 272(34): 21045 - 21051. [Abstract] [Full Text] [PDF]